Further studies combining metformin treatment (4–16 mM) with low-dose celecoxib (an anti-inflammatory drug, 4–16 μM) show staunch reduction in NSCLC cell migration, invasions, and increased expression of p53, resulting in cell cycle arrest [41]. Here, TP53 is linked to non-small cell lung carcinoma.